DURECT (NASDAQ:DRRX) Posts Earnings Results, Misses Expectations By $0.12 EPS

DURECT (NASDAQ:DRRX) announced its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.12), Zacks reports. DURECT had a negative return on equity of 300.62% and a negative net margin of 198.58%. The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $6.91 million.

DURECT Price Performance

DRRX opened at $0.81 on Friday. The stock has a market cap of $25.02 million, a price-to-earnings ratio of -1.32 and a beta of 0.91. DURECT has a 12-month low of $0.70 and a 12-month high of $1.88. The business has a 50 day moving average of $0.80 and a 200-day moving average of $1.01.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DRRX shares. StockNews.com started coverage on DURECT in a research report on Thursday. They issued a “sell” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research note on Thursday.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.